Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
Immunotherapy has shown significant improvement in the survival of patients with hepatocellular carcinoma (HCC) compared to TKIs as first-line treatment. Unfortunately, approximately 30% of HCC exhibits intrinsic resistance to ICIs, making new therapeutic combinations urgently needed. The dysregulat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850040393444360192 |
|---|---|
| author | Annapaola Montagner Andrea Arleo Fabrizia Suzzi Antonino B. D’Assoro Fabio Piscaglia Laura Gramantieri Catia Giovannini |
| author_facet | Annapaola Montagner Andrea Arleo Fabrizia Suzzi Antonino B. D’Assoro Fabio Piscaglia Laura Gramantieri Catia Giovannini |
| author_sort | Annapaola Montagner |
| collection | DOAJ |
| description | Immunotherapy has shown significant improvement in the survival of patients with hepatocellular carcinoma (HCC) compared to TKIs as first-line treatment. Unfortunately, approximately 30% of HCC exhibits intrinsic resistance to ICIs, making new therapeutic combinations urgently needed. The dysregulation of the Notch signaling pathway observed in HCC can affect immune cell response, reducing the efficacy of cancer immunotherapy. Here, we provide an overview of how Notch signaling regulates immune responses and present the therapeutic rationale for combining Notch signaling inhibition with ICIs to improve HCC treatment. Moreover, we propose using exosomes as non-invasive tools to assess Notch signaling activation in hepatic cancer cells, enabling accurate stratification of patients who can benefit from combined strategies. |
| format | Article |
| id | doaj-art-267a97bd03794ddebacf693a2607690d |
| institution | DOAJ |
| issn | 2218-273X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-267a97bd03794ddebacf693a2607690d2025-08-20T02:56:06ZengMDPI AGBiomolecules2218-273X2024-12-011412158110.3390/biom14121581Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined TherapiesAnnapaola Montagner0Andrea Arleo1Fabrizia Suzzi2Antonino B. D’Assoro3Fabio Piscaglia4Laura Gramantieri5Catia Giovannini6Department of Medical and Surgical Sciences, Bologna University, 40138 Bologna, ItalyDepartment of Medical and Surgical Sciences, Bologna University, 40138 Bologna, ItalyDepartment of Medical and Surgical Sciences, Bologna University, 40138 Bologna, ItalyDepartment of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55902, USADepartment of Medical and Surgical Sciences, Bologna University, 40138 Bologna, ItalyDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyDepartment of Medical and Surgical Sciences, Bologna University, 40138 Bologna, ItalyImmunotherapy has shown significant improvement in the survival of patients with hepatocellular carcinoma (HCC) compared to TKIs as first-line treatment. Unfortunately, approximately 30% of HCC exhibits intrinsic resistance to ICIs, making new therapeutic combinations urgently needed. The dysregulation of the Notch signaling pathway observed in HCC can affect immune cell response, reducing the efficacy of cancer immunotherapy. Here, we provide an overview of how Notch signaling regulates immune responses and present the therapeutic rationale for combining Notch signaling inhibition with ICIs to improve HCC treatment. Moreover, we propose using exosomes as non-invasive tools to assess Notch signaling activation in hepatic cancer cells, enabling accurate stratification of patients who can benefit from combined strategies.https://www.mdpi.com/2218-273X/14/12/1581NotchPD-1PD-L1hepatocellular carcinoma (HCC)immunotherapycombination therapy |
| spellingShingle | Annapaola Montagner Andrea Arleo Fabrizia Suzzi Antonino B. D’Assoro Fabio Piscaglia Laura Gramantieri Catia Giovannini Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies Biomolecules Notch PD-1 PD-L1 hepatocellular carcinoma (HCC) immunotherapy combination therapy |
| title | Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies |
| title_full | Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies |
| title_fullStr | Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies |
| title_full_unstemmed | Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies |
| title_short | Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies |
| title_sort | notch signaling and pd 1 pd l1 interaction in hepatocellular carcinoma potentialities of combined therapies |
| topic | Notch PD-1 PD-L1 hepatocellular carcinoma (HCC) immunotherapy combination therapy |
| url | https://www.mdpi.com/2218-273X/14/12/1581 |
| work_keys_str_mv | AT annapaolamontagner notchsignalingandpd1pdl1interactioninhepatocellularcarcinomapotentialitiesofcombinedtherapies AT andreaarleo notchsignalingandpd1pdl1interactioninhepatocellularcarcinomapotentialitiesofcombinedtherapies AT fabriziasuzzi notchsignalingandpd1pdl1interactioninhepatocellularcarcinomapotentialitiesofcombinedtherapies AT antoninobdassoro notchsignalingandpd1pdl1interactioninhepatocellularcarcinomapotentialitiesofcombinedtherapies AT fabiopiscaglia notchsignalingandpd1pdl1interactioninhepatocellularcarcinomapotentialitiesofcombinedtherapies AT lauragramantieri notchsignalingandpd1pdl1interactioninhepatocellularcarcinomapotentialitiesofcombinedtherapies AT catiagiovannini notchsignalingandpd1pdl1interactioninhepatocellularcarcinomapotentialitiesofcombinedtherapies |